|
PPP2CB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.10680045526135E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.13200004925318E-09 |
| Normal-vs-Stage2 |
7.8772000033922E-10 |
| Normal-vs-Stage3 |
1.0189999954946E-09 |
| Normal-vs-Stage4 |
5.81830139623207E-11 |
| Stage1-vs-Stage2 |
2.367000E-01 |
| Stage1-vs-Stage3 |
6.752000E-01 |
| Stage1-vs-Stage4 |
9.966100E-02 |
| Stage2-vs-Stage3 |
4.462600E-01 |
| Stage2-vs-Stage4 |
7.528200E-01 |
| Stage3-vs-Stage4 |
2.378600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.30450000696203E-10 |
| Normal-vs-AfricanAmerican |
3.50450000000668E-05 |
| Normal-vs-Asian |
5.83769999007444E-09 |
| Caucasian-vs-AfricanAmerican |
8.813800E-02 |
| Caucasian-vs-Asian |
9.821000E-01 |
| AfricanAmerican-vs-Asian |
1.652560E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.38030048396831E-10 |
| Normal-vs-Female |
5.76069969504545E-10 |
| Male-vs-Female |
5.718200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.5975999956861E-09 |
| Normal-vs-Age(41-60Yrs) |
5.75619996112664E-10 |
| Normal-vs-Age(61-80Yrs) |
2.35470531961823E-11 |
| Normal-vs-Age(81-100Yrs) |
4.142000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.774000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.628160E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.509400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.031420E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.698000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.612000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.452400E-01 |
| Classical-VS-Follicular |
1.418300E-02 |
| Classical-VS-Other |
8.536800E-01 |
| Classical-VS-Normal |
6.85180001624985E-09 |
| Tall-VS-Follicular |
2.881600E-01 |
| Tall-VS-Other |
8.318400E-01 |
| Tall-VS-Normal |
6.63910004750079E-09 |
| Follicular-VS-Other |
5.327400E-01 |
| Follicular-VS-Normal |
1.01900043958381E-10 |
| Other-VS-Normal |
1.081620E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.75329767265953E-11 |
| Normal-vs-N1 |
1.68460001503945E-09 |
| N0-vs-N1 |
7.962800E-01 |
|
|
